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A B S T R A C T
Purpose
Nivolumab provides clinical benefit (objective response rate [ORR], 31%; 95% CI, 20.8 to 42.9;
disease control rate, 69%; 12-month overall survival [OS], 73%) in previously treated patients with
DNAmismatch repair–deficient (dMMR)/microsatellite instability–high (MSI-H) metastatic colorectal
cancer (mCRC); nivolumab plus ipilimumab may improve these outcomes. Efficacy and safety
results for the nivolumab plus ipilimumab cohort of CheckMate-142, the largest single-study report
of an immunotherapy combination in dMMR/MSI-H mCRC, are reported.
Patients and Methods
Patients received nivolumab 3 mg/kg plus ipilimumab 1 mg/kg once every 3 weeks (four doses)
followed by nivolumab 3 mg/kg once every 2 weeks. Primary end point was investigator-assessed
ORR.
Results
Of 119 patients, 76% had received $ two prior systemic therapies. At median follow-up of
13.4 months, investigator-assessed ORR was 55% (95% CI, 45.2 to 63.8), and disease control rate
for $ 12 weeks was 80%. Median duration of response was not reached; most responses (94%)
were ongoing at data cutoff. Progression-free survival rates were 76% (9 months) and 71%
(12 months); respective OS rates were 87% and 85%. Statistically significant and clinically
meaningful improvements were observed in patient-reported outcomes, including functioning,
symptoms, and quality of life. Grade 3 to 4 treatment-related adverse events (AEs) occurred in 32%
of patients and were manageable. Patients (13%) who discontinued treatment because of study
drug-related AEs had an ORR (63%) consistent with that of the overall population.
Conclusion
Nivolumab plus ipilimumab demonstrated high response rates, encouraging progression-free
survival and OS at 12 months, manageable safety, and meaningful improvements in key patient-
reported outcomes. Indirect comparisons suggest combination therapy provides improved efficacy
relative to anti–programmed death-1 monotherapy and has a favorable benefit-risk profile. Nivo-
lumab plus ipilimumab provides a promising new treatment option for patients with dMMR/MSI-H
mCRC.
J Clin Oncol 36:773-779. © 2018 by American Society of Clinical Oncology
INTRODUCTION
Colorectal cancer (CRC) remains a leading cause of
cancer-related death worldwide, with a 5-year sur-
vival rate of 14% in patients with metastatic CRC
(mCRC).1,2 Patients with DNA mismatch repair–
deficient (dMMR)/microsatellite instability–high
(MSI-H) mCRC (approximately 4% of patients)3-5
are a distinct biomarker-defined population that
benefits less from conventional chemotherapy;
evolving data show poorer outcomes in key clinical
parameters in these patients compared with those
with MMR-proficient/microsatellite stable mCRC.4-9
Evidence from recent studies of anti–
programmed death-1 (PD-1) checkpoint in-
hibitors has demonstrated that dMMR/MSI-H
status is a biomarker predictive of response to
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anti–PD-1 therapy3,10-13; thus, universal dMMR/MSI-H testing is
recommended for patients with mCRC.14-16 In the monotherapy
cohort of CheckMate-142, nivolumab, the fully human immu-
noglobulin G4 monoclonal antibody inhibitor of PD-1, provided
durable responses (investigator-assessed objective response rate
[ORR], 31%; median duration of response [DOR], not yet reached
with median follow-up of 12.0 months), sustained disease control
(disease control rate [DCR] $ 12 weeks, 69%), progression-free
survival (PFS) rates of 54% (9 months) and 50% (12 months), and
overall survival (OS) rates of 78% (9 months) and 73%
(12 months) in previously treated patients with dMMR/MSI-H
mCRC.11 Nivolumab is approved in the United States for the
treatment of adult and pediatric (age $ 12 years) patients with
dMMR/MSI-H mCRC who had disease progression after treat-
ment with a fluoropyrimidine, oxaliplatin, and irinotecan.17 Ipi-
limumab is a fully human immunoglobulin G1 monoclonal
antibody that targets the cytotoxic T-cell lymphocyte antigen-4
(CTLA-4) checkpoint receptor.18 In preclinical and clinical set-
tings, the combination of nivolumab plus ipilimumab has provided
enhanced activity over nivolumab monotherapy,19-21 and the
combination is approved for the treatment of metastatic melanoma
using specific dosing (nivolumab 1 mg/kg plus ipilimumab 3 mg/kg
once every 3 weeks for four doses followed by nivolumab 3 mg/kg
once every 2 weeks).17
Presented here are efficacy, safety, biomarker, and patient-
reported outcome (PRO) analyses from the complete population of
patients in the nivolumab plus ipilimumab cohort of CheckMate-
142, which, to our knowledge, is the largest single-study report of
combination immunotherapies in patients with dMMR/MSI-H
mCRC.
PATIENTS AND METHODS
Study Design and Participants
CheckMate-142 is an ongoing, multicenter, open-label, phase II trial.
Patients in the nivolumab plus ipilimumab cohort were treated at 28 sites
in eight countries. Eligible patients were age $ 18 years and had histo-
logically confirmed recurrent CRC or mCRC assessed as dMMR and/or
MSI-H per local guidelines. Patients had disease progression on or after or
were intolerant of $ one prior systemic treatment that included a fluo-
ropyrimidine and oxaliplatin or irinotecan; however, patients who refused
chemotherapy were eligible. Any chemotherapy, curative-intent radio-
therapy, or biologic or investigational therapy must have been com-
pleted . 28 days before treatment initiation; focal palliative radiotherapy
must have been completed $ 2 weeks before starting treatment. Eligible
patients had an Eastern Cooperative Oncology Group performance status
of # 1 and measurable disease per Response Evaluation Criteria in Solid
Tumors (RECIST; version 1.1).22,23 Patients were excluded for active,
known, or suspected autoimmune disease; conditions requiring cortico-
steroids (prednisone equivalents . 10 mg per day) or other immuno-
suppressive medication # 14 days before starting treatment; other serious
or uncontrolled medical disorders; active brain or leptomeningeal me-
tastases; or prior malignancy within the previous 3 years except for cured
select localized cancers. Additional exclusion criteria included prior
treatment with an anti–PD-1, anti–programmed death-ligand 1/2 (PD-L1/
PD-L2), anti–CTLA-4, or other agent targeting T-cell costimulation or
immune checkpoint pathways.
Patients received nivolumab 3 mg/kg (60-minute intravenous [IV]
infusion) and ipilimumab 1 mg/kg (90-minute IV infusion) once every
3 weeks for four doses and then nivolumab 3 mg/kg IVonce every 2 weeks
(Appendix Fig A1, online only) until disease progression, discontinuation
because of toxicity, death, withdrawal of consent, or study end. Dose
modifications were not permitted. Dose interruptions for treatment-
related adverse events (TRAEs) were allowed (Appendix, online only).
Treatment beyond initial progression was permitted if the patient tolerated
and benefited from study treatment per investigator assessment.
Study protocol and amendments were approved by the institutional
review board or independent ethics committee at each participating center.
CheckMate-142 was conducted in accordance with the Declaration of
Helsinki and Good Clinical Practice guidelines, and patients provided
written informed consent before enrollment.
Outcomes
The primary end point was investigator-assessed ORR (patients with
best response of complete response [CR] or partial response [PR] divided
by the number of treated patients) per RECIST (version 1.1). Secondary
end points included ORR per blinded independent central review (BICR)
and DCR (patients with best response of CR, PR, or stable disease for
$ 12 weeks divided by the number of treated patients). Other end points
included safety and tolerability, PFS (time from first dose to first docu-
mented progression or death resulting from any cause, whichever occurred
first) per investigator assessment and BICR, OS (time from the first dose to
death), association between biomarker expression and efficacy, and
changes from baseline in PROs.
Assessments
Tumors were assessed using computed tomography or magnetic
resonance imaging per RECIST (version 1.1) # 28 days before the first
dose (baseline), followed by every 6 weeks for 24 weeks and every 12 weeks
thereafter until the time of disease progression or discontinuation. All
responses had to be confirmed by another scan$ 4 weeks later. Safety was
assessed per Common Terminology Criteria for Adverse Events (version
4.0) continuously throughout treatment and for $ 100 days after treat-
ment discontinuation.24 Patients were then observed for survival every
3 months. PRO analyses were performed before the first dose of study
treatment and every 6 weeks thereafter using the European Organisation
for Research and Treatment of Cancer (EORTC) Core Quality of Life
Questionnaire (QLQ-C30) and three-level five-dimensional EuroQol in-
strument (EQ-5D).25,26 EORTC QLQ-C30 assesses symptoms, function-
ing, and quality of life (QOL) using scales from 0 to 100, with higher scores
indicating better functioning and QOL or worse symptoms. For each scale,
a$ 10-point change from baseline was regarded as clinically meaningful.27
EQ-5D assesses problems (none, some, or extreme) in five health di-
mensions (mobility, self-care, usual activities, pain or discomfort, and
anxiety or depression). EQ-5D also has a visual analog scale, which allows
patients to rate their health; scores range from 0 to 100 (higher values
indicate better perceived health), and changes from baseline of$ 7 points
were deemed clinically meaningful.28
Tumor MMR and/or MSI status was evaluated before screening per
local guidelines using immunohistochemistry and/or polymerase chain
reaction (PCR). Samples with loss of expression of$ one mismatch repair
protein per immunohistochemistry were identified as dMMR. Tumor
samples were identified as MSI-H using PCR if instability was found in
$ two markers when five loci were tested, in$ three of four markers when
one PCR failed, or $ 30% of markers when . five loci were tested.
Additional MMR/MSI testing criteria are provided in the Appendix. Tumor
PD-L1 expression ($ 1% or , 1%) was determined using archival or
pretreatment biopsy tissue with the Dako 28-8 pharmDx immunohisto-
chemistry assay (Dako North America, Carpinteria, CA). Positive PD-L1
staining was defined as complete circumferential or partial linear plasma
membrane staining. BRAF/KRAS mutation status was determined at the
time of screening per local guidelines. Lynch syndrome status was char-
acterized as positive or negative by investigators based on medical history
collected from clinical records; genetic testing for Lynch syndrome was not
mandated in the protocol.
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Statistical Analyses
Patients were enrolled using a Simon two-stage study design. Per the
protocol, only patients confirmed as MSI-H by a central laboratory were
used to determine the number of responders necessary to progress from
stage one to stage two. If# six of the first 19 patients confirmed as MSI-H
by a central laboratory had an objective response (CR or PR) in stage one,
enrollment would end; however, if$ seven of these patients had a response
in stage one, additional patients would be enrolled in stage two. Efficacy
and safety were analyzed in all patients (dMMR/MSI-H per local labo-
ratory) who received $ one dose of study treatment. Response-evaluable
patients had baseline and $ one on-study tumor assessment. The 95% CI
for ORR was estimated using the Clopper and Pearson method. The
Kaplan-Meier product-limit method was used to determine medians for
DOR, PFS, and OS; corresponding 95% CIs were calculated based on log-
log transformation. Descriptive statistics were used to characterize patient
characteristics, PRO analyses, and safety. Missing PRO data were treated as
indicated by the scoring manuals.25 For inferential PRO analyses, changes
in mean scores over time were analyzed using linear mixedmodels adjusted
for baseline score.29 Statistical analyses were performed using SAS software
(version 9.02; SAS Institute, Cary, NC).
RESULTS
Baseline Characteristics and Patient Disposition
Patients were enrolled in the nivolumab plus ipilimumab
combination cohort of CheckMate-142 from May 2015 through
September 2016. Twenty-seven patients were enrolled in stage one,
of whom 19 were confirmed as MSI-H per central laboratory. A
sufficient number of confirmed investigator-assessed responses
were reported in these 19 patients, and additional patients (n = 92)
were enrolled in stage two per the protocol. At data cutoff (July
2017), 119 patients with dMMR/MSI-H mCRC were treated in
stages one and two. Median duration of follow-up (potential time
on study from first dose to data cutoff) was 13.4 months (range,
9 to 25 months). Most patients (68%) were age , 65 years, and
76% had received $ two prior lines of systemic therapy (Table 1);
69% of patients received prior chemotherapy with oxaliplatin,
irinotecan, and a fluoropyrimidine. BRAF and KRAS mutations
were identified in 24% and 37% of patients, respectively.
Most patients (n = 75; 63%) were still receiving treatment at
data cutoff. Among patients (n = 44) who discontinued therapy,
the primary reasons were disease progression (n = 23; 19%), AEs
related to study drug (n = 16; 13%), and AEs unrelated to study
drug (n = 2; 2%); additional reasons included loss to follow-up,
death, and patient did not present for restaging (each n = 1; 1%). A
median of 24 doses of nivolumab (range, one to 55 doses) and four
of ipilimumab (range, one to four doses) were received; 76% and
85% of patients had a relative dose intensity$ 90% for nivolumab
and ipilimumab, respectively.
Efficacy
Of 119 patients, 54.6% (95% CI, 45.2 to 63.8) achieved an
objective response per investigator assessment, including 3.4%
with CRs and 51.3% with PRs (Table 2). Disease control for
$ 12 weeks was achieved in 80% (95%CI, 71.5 to 86.6) of patients.
Outcomes per investigator assessment were 91% concordant with
BICR results. The ORR per BICR was 49% (95% CI, 39.5 to 58.1),
including 4% of patients with CRs and 45% with PRs; DCR for
$ 12 weeks was observed in 79% (95% CI, 70.6 to 85.9) of patients
(Appendix Table A1, online only). Additional efficacy outcomes
per BICR are presented in Appendix Figures A2 and A3 (online
only). Investigator-assessed responses were observed irrespective of
tumor BRAF or KRAS mutation status, tumor PD-L1 expression,
Table 1. Baseline Patient Demographic and Clinical Characteristics (N = 119)
Characteristic No. (%)
Age, years
Median 58.0
Range 21-88
, 65 81 (68)
Male sex 70 (59)
Race
White 109 (92)
Black 2 (2)
Asian 3 (3)
Other 5 (4)
ECOG performance status
0 54 (45)
1 65 (55)
Disease stage at diagnosis
II 14 (12)
III 52 (44)
IV 53 (45)
Primary tumor location
Right colon 65 (55)
Left and sigmoid colon 30 (25)
Transverse colon 15 (13)
Rectum 6 (5)
Colon, NOS 3 (3)
No. of prior systemic treatments
0 1 (1)
1 27 (23)
2 43 (36)
$ 3 48 (40)
Prior therapies received
Fluoropyrimidines (5-fluorouracil or capecitabine) 118 (99)
Oxaliplatin 111 (93)
Irinotecan 87 (73)
VEGF inhibitors* 68 (57)
EGFR inhibitors† 35 (29)
Regorafenib 11 (9)
Trifluridine/tipiracil 2 (2)
Other experimental drugs 3 (3)
Other chemotherapy 8 (7)
Prior radiotherapy 20 (17)
Mutation status
BRAF/KRAS wild type 31 (26)
BRAF mutation 29 (24)
KRAS mutation 44 (37)
Unknown 15 (13)
Tumor PD-L1 expression quantifiable at baseline
$ 1% 26 (22)
, 1% 65 (55)
Unknown 28 (24)
Clinical history of Lynch syndrome‡
Yes 35 (29)
No 31 (26)
Unknown 53 (45)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal
growth factor receptor; NOS, not otherwise specified; PD-L1, programmed
death-ligand 1; VEGF, vascular endothelial growth factor.
*VEGF inhibitors included bevacizumab, aflibercept, and ramucirumab.
†EGFR inhibitors included cetuximab and panitumumab.
‡Lynch syndrome designation was based on the clinical records of patients at
sites in countries where this reporting was permitted (excluded Italy).
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or clinical history of Lynch syndrome (Appendix Table A2, online
only). The ORR and DCR in patients with a BRAF mutation were
55% and 79%, respectively.
Among evaluable patients (n = 115), 78% had a reduction in
tumor burden from baseline per investigator assessment (Fig 1A).
Median time to response was 2.8 months (range, 1 to 14 months).
Responses were durable, with 94% of responders having ongoing
responses at data cutoff, and 83% had responses lasting
$ 6 months (Fig 1B). The median DOR was not reached (95% CI,
not estimable). Median PFS per investigator assessment was not
reached after 33 PFS events; 9- and 12-month PFS rates were 76%
(95%CI, 67.0 to 82.7) and 71% (95%CI, 61.4 to 78.7), respectively
(Fig 2A). The median OS was not reached (95% CI, not estimable),
and the 9- and 12-month OS rates were 87% (95%CI, 80.0 to 92.2)
and 85% (95% CI, 77.0 to 90.2), respectively (Fig 2B).
PROs
PRO questionnaire completion rates ranged from 80% to
100% through week 91, after which, 10 patients were eligible for
on-treatment assessment (Appendix Table A3, online only). While
on study, most patients ($ 60%) maintained functioning and
global health status/QOL without worsening of symptoms per
EORTC QLQ-C30 (Appendix Table A4, online only). After ad-
justment for baseline score, statistically significant and clinically
meaningful improvements (mean change from baseline $ 10
points) were reported in key PROs, including symptoms, func-
tioning, and global health status/QOL by week 13 or earlier, and
these improvements were largely maintained in patients receiving
treatment (Appendix Fig A4A to Fig A4H, online only). Although
not demonstrating a mean change from baseline $ 10 points
at most on-treatment time points, statistically significant im-
provements were reported for nausea or vomiting, dyspnea, di-
arrhea, cognitive functioning, and physical functioning (Appendix
Fig A4I to Fig A4M). Per EQ-5D, 6% (self-care) to 63% (pain) of
patients reported health problems at baseline; notable (. 10%)
reductions in patients reporting health problems were observed as
early as week 13 for all dimensions (Appendix Table A5, online
only). After adjustment for baseline score, statistically significant
and clinically meaningful improvements in the visual analog scale
of EQ-5Dwere observed by week 19, and these improvements were
maintained in patients continuing treatment (Appendix Fig A5,
online only).
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Fig 1. (A) Waterfall plot depicting the best change from baseline in target lesion
size per investigator assessment. (B) Characteristics of patients with a response
per investigator assessment. Bars indicate the duration of progression-free sur-
vival (PFS). DOR, duration of response; TTR, time to response. (*) Patient with
confirmed response.
Table 2. ORR, Best Overall Response, and DCR per Investigator Assessment
(N = 119)
Response No. (%) 95% CI
ORR 65 (55) 45.2 to 63.8
Best overall response
Complete response 4 (3)
Partial response 61 (51)
Stable disease 37 (31)
Progressive disease 14 (12)
Not determined 3 (3)
Disease control for $ 12 weeks 95 (80) 71.5 to 86.6
Abbreviations: DCR, disease control rate; ORR, objective response rate.
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Safety
Any-grade TRAEs were reported in 73% of patients, with the
most common being diarrhea (22%), fatigue (18%), and pruritus
(17%; Table 3). Thirty-two percent of patients experienced a grade
3 (27%) or 4 (5%) TRAE, with elevated AST and/or ALT (11%),
elevated lipase (4%), anemia (3%), and colitis (3%) occurring in.
two patients. Serious TRAEs were reported in 23% (any grade) and
20% (grade 3 to 4) of patients. TRAEs led to discontinuation in
13% (any grade) and 10% (grade 3 to 4) of patients; the only events
leading to discontinuation in . one patient were autoimmune
hepatitis and acute kidney injury (2% each). Among patients (n = 16)
whose primary reason for discontinuing treatment was an AE
related to study drug, the ORR was 63%, DCR for$ 12 weeks was
81%, and median DOR was not reached, consistent with efficacy
results in the overall population. Any-grade select TRAEs (events
with potential immunologic etiology) analyzed by organ category
occurred in 29% (skin), 25% (endocrine), 23% (GI), 19% (he-
patic), and 5% (pulmonary, renal) of patients; the median time to
onset ranged from 5.2 to 12.6 weeks (Appendix Table A6, online
only). Some patients (range, 22% to 56%) received immune-
modulating medication to manage their select TRAEs. With the
use of protocol-specified management algorithms, select TRAEs
resolved in most patients (range, 71% to 96%), except for en-
docrine TRAEs, which resolved in 40% of patients. The median
time to resolution of nonendocrine select TRAEs ranged from 1.5
to 9.0 weeks; the median time to resolution of endocrine TRAEs
was not reached. No treatment-related deaths were reported.
DISCUSSION
Although the development of PD-1 inhibitors provided an im-
portant advance in the treatment of patients with dMMR/MSI-H
mCRC,3,10-12 an opportunity remains to explore rational combi-
nations to further improve these results. Nivolumab and ipili-
mumab act synergistically to promote T-cell antitumor activity
through complementary mechanisms of action.17,18,20,21 Results of
the nivolumab plus ipilimumab cohort reported here demonstrate
a manageable safety profile and robust clinical activity, with an
ORR of 55%, DCR for $ 12 weeks of 80%, PFS rates of 76%
(9months) and 71% (12months), and OS rates of 87% (9months)
and 85% (12 months); responses in patients with dMMR/MSI-H
mCRC were observed irrespective of tumor PD-L1 expression,
BRAF/KRAS mutation status, or clinical history of Lynch syn-
drome. The favorable benefit-risk profile seen in this cohort
suggests a role for combination checkpoint inhibitor therapy in the
treatment of patients with dMMR/MSI-H mCRC.
In CheckMate-142, monotherapy and combination therapy
cohorts were neither randomly assigned nor designed for formal
comparison; however, considering the limitations of an indirect
comparison, nivolumab plus ipilimumab provided a numerically
higher response rate (55%; 95% CI, 45 to 64) relative to the re-
sponse rate (31%; 95% CI, 21 to 43) with nivolumab monotherapy
in a similar population of patients (n = 74) with a comparable
median follow-up time.11 Likewise, with the limitations of cross-
trial comparisons in mind, the response rate with nivolumab plus
ipilimumab in CheckMate-142 was numerically higher relative to
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Fig 2. Kaplan-Meier plots of (A) progression-free survival (PFS) per investigator assessment and (B) overall survival (OS) in all patients.
Table 3. Summary of TRAEs With Nivolumab in Combination With Ipilimumab
(N = 119)
TRAE
No. (%)
Grade 1-2 Grade 3 Grade 4
Any TRAE 49 (41) 32 (27) 6 (5)
Diarrhea* 24 (20) 2 (2) 0
Fatigue* 19 (16) 2 (2) 0
Pruritus* 18 (15) 2 (2) 0
Pyrexia* 18 (15) 0 0
Increased AST* 8 (7) 9 (8) 0
Hypothyroidism* 15 (13) 1 (1) 0
Nausea* 14 (12) 1 (1) 0
Increased ALT* 6 (5) 8 (7) 0
Rash* 11 (9) 2 (2) 0
Hyperthyroidism* 13 (11) 0 0
NOTE. TRAEs were assessed during treatment and for up to 30 days after the
last dose of study treatment according to National Cancer Institute Common
Terminology Criteria for Adverse Events (version 4.0).
Abbreviation: ALT, alanine aminotransferase; AST, aspartate aminotransferase;
TRAE, treatment-related adverse event.
*Reported in . 10% of patients.
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the rate (28%; 95% CI, 17 to 41) reported with pembrolizumab
monotherapy in previously treated patients (n = 61) with MSI-H
mCRC in KEYNOTE-164, of whom 15% had BRAFmutations and
90% had received $ two prior lines of therapy.12,13 Although
results with pembrolizumab monotherapy in KEYNOTE-016
showed numerically higher response rates (57%; 95% CI, 39 to
73), the limited number of patients (n = 28) and sites (n = 6;
United States only) as well as a high rate of Lynch syndrome (54%)
may have biased findings in this study.10,30,31 In an indirect
comparison of PFS and OS, estimated 12-month PFS (71%) and
OS (85%) rates with nivolumab plus ipilimumab were numerically
higher relative to those observed with anti–PD-1 monotherapies
(nivolumab [CheckMate-142]: PFS, 50% and OS, 73%; pem-
brolizumab [KEYNOTE-164]: PFS, 34% and OS, 72%).11-13
Despite the caveats associated with indirect comparisons, Kaplan-
Meier plots of PFS and OS with nivolumab monotherapy and
nivolumab plus ipilimumab combination therapy in CheckMate-
142 suggest that the addition of ipilimumab may improve the long-
term clinical benefit of nivolumab (Fig 3)11; additional investigation
is warranted.
Nivolumab plus ipilimumab combination therapy has been
investigated using different doses and schedules in other tumor
types, and the safety profile has been found to be influenced by the
ipilimumab dose.20,21,32 In mCRC, nivolumab 3 mg/kg plus ipi-
limumab 1 mg/kg once every 3 weeks was selected based on the
safety cohort of CheckMate-142.33 At this dose, a majority of
patients received all four doses of ipilimumab, and the safety
profile was manageable. Importantly, the incidence of diarrhea
and colitis with combination therapy did not seem elevated in this
population compared with that in patients with other solid
tumors.20,21,32 The rate of any-grade and grade 3 to 4 TRAEs was
73% and 32%, respectively, and efficacy was maintained (ORR,
63%; DCR, 81%) in patients who discontinued treatment because
of study drug–related AEs.11 Nonendocrine select TRAEs resolved
in most patients (range, 71% to 96%) in a median of 1.5 to 9.0
weeks with the use of protocol-specified management algorithms;
endocrine TRAEs resolved in 40% of patients. Of note, the overall
rate of any-grade TRAEs in the combination therapy cohort was
comparable to that in the nivolumab monotherapy cohort (70%),
and the rates of discontinuation because of study drug-related
AEs (13% and 7%, respectively) were modest in each cohort.11
Importantly, patients exhibited statistically significant and clin-
ically meaningful on-treatment improvements with combination
therapy in key PROs, including symptoms, functioning, and
QOL.
In conclusion, the results presented here demonstrate that
nivolumab in combination with ipilimumab provided durable
responses, high DCR, encouraging survival rates, manageable
safety, and meaningful improvements in key PROs in previously
treated patients with dMMR/MSI-H mCRC. Considering the
indirect comparisons that suggest numerically higher response
rates and an improved long-term clinical benefit with nivolumab
plus ipilimumab relative to anti–PD-1 monotherapy, and the fa-
vorable benefit-risk profile of combination therapy, nivolumab
plus ipilimumab represents a promising new treatment option in
these patients. Evaluation of nivolumab plus ipilimumab as a first-
line therapy (phase II) in patients with dMMR/MSI-H mCRC is
ongoing.
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Appendix
Dose Interruptions for Treatment-Related Adverse Events
Dose interruptions for treatment-related adverse events (TRAEs) were allowed until resolution of these events or for# 6 weeks
from the last treatment. Patients could resume treatment at the next scheduled dose after TRAE resolution; however, patients were
not to skip administration of nivolumab plus ipilimumab (if toxicity allowed) to ensure that each patient received four doses of
combination therapy. Patients with interruptions lasting . 6 weeks were discontinued from the study, except when dosing was
interrupted for prolonged steroid tapers to manage TRAEs or for non-TRAEs (required approval).
Local Laboratory Criteria for Determining Mismatch Repair–Proficient and Microsatellite Instability Status
DNA mismatch repair deficiency determined by immunohistochemistry refers to the loss of expression of $ one mismatch
repair protein (ie, MLH1, MSH2, MSH6, or PMS2).
Microsatellite instability–high (MSI-H) is most frequently determined by polymerase chain reaction. MSI-H in tumors refers
to changes in $ two of the five National Cancer Institute–recommended panels of microsatellite markers in tumor tissue. The
original Bethesda guidelines proposed a panel of five microsatellite markers for the uniform analysis of MSI in Lynch syndrome
(Umar A, et al: J Nat Cancer Inst 96:261-268, 2004). Individual testing sites may use a slightly different panel of markers in-
corporating alternative mononucleotide and/or dinucleotide markers. Regardless of the panel of markers, samples with instability
in$ 30% of these markers are defined as MSI-H, whereas those with, 30% unstable markers are designated as MSI-low. Samples
with no detectable alterations are microsatellite stable.
Central Laboratory Criteria for Determining Microsatellite Instability in Combination Stage One
In combination stage one of the two-stage Simon design, a central laboratory was used to confirm the MSI-H status of tumor
tissue collected at baseline by polymerase chain reaction using modified Bethesda criteria. This panel included twomononucleotide
(BAT-25 and BAT-26) and three dinucleotide (D5S346, D2S123, and D17S250) repeats (Umar A, et al: J Nat Cancer Inst 96:261-
268, 2004). Samples with instability in $ two of these markers were defined as MSI-H, whereas those with one unstable marker
were designated as MSI-low. Samples with no detectable alterations were identified as microsatellite stable.
Week 1 4 10 13 157
Nivo + Ipi Nivo + Ipi Nivo + Ipi Nivo + Ipi
17+
Nivolumab 3 mg/kg + ipilimumab 1 mg/kg
once every 3 weeks × four doses
Nivolumab 3 mg/kg
once every 2 weeks
Nivo Nivo Nivo
Fig A1. Nivolumab (Nivo) plus ipilimumab (Ipi) dosing schedule in CheckMate-142.
jco.org © 2018 by American Society of Clinical Oncology
Nivolumab Plus Ipilimumab in dMMR/MSI-H Metastatic CRC
Downloaded from ascopubs.org by 217.174.121.240 on June 4, 2018 from 217.174.121.240
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
–30
20
Be
st
 R
ed
uc
tio
n 
Fr
om
 B
as
el
in
e 
in
 T
ar
ge
t L
es
io
n 
Si
ze
 (%
)
100
50
75
0
–50
–75
–25
25
–100
A
***** ********************************* *************
**
*
**
0 6 12 18 24 30 36 42 48 54
Time (weeks)
Pa
tie
nt
s 
W
ith
 R
es
po
ns
e
60 66 72 78 84 90 96 10
2
10
8
11
4
Median (range) TTR, months: 2.8 (1 to 11)
Median (95% CI) DOR, months: not reached (not estimable)
Death
First response
On treatment
Off treatment
Censored with ongoing response
B
Fig A2. (A) Best reduction from baseline in target lesion size, and (B) charac-
teristics of response per blinded independent central review. DOR, duration of
response; TTR, time to response. (*) Patient with confirmed response
© 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Overman et al
Downloaded from ascopubs.org by 217.174.121.240 on June 4, 2018 from 217.174.121.240
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
100
90
80
70
60
50
40
30
20
10
0 3 6 9 1512 21 2418
PF
S 
(%
)
27
Time (months)
119 90 81 71 1337 11 412 0
No. at risk:
Fig A3. Progression-free survival (PFS) per blinded independent central review.
jco.org © 2018 by American Society of Clinical Oncology
Nivolumab Plus Ipilimumab in dMMR/MSI-H Metastatic CRC
Downloaded from ascopubs.org by 217.174.121.240 on June 4, 2018 from 217.174.121.240
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
Le
as
t S
qu
ar
es
 M
ea
n 
Ch
an
ge
Fr
om
 B
as
el
in
e 
(9
5%
 C
I)
–40
–30
–20
–10
0
10
20
30
B
et
te
r
Time (weeks)
W
o
rs
e
7 13 19 25 31 37 43 49 55 61 67 73 79 85 910
**
** ****
****
**
**
** **
** **
**
**
No. at risk:
**
107 100 85 79 76 68 69 72 58 44 31 16 10 11 10 10
Le
as
t S
qu
ar
es
 M
ea
n 
Ch
an
ge
Fr
om
 B
as
el
in
e 
(9
5%
 C
I)
No. at risk: 107 100 85 79 76 68 68 72 58 45 31 16 10 11 10 10
–40
–30
–20
–10
0
10
20
30
B
et
te
r
Time (weeks)
W
o
rs
e
**
** **
******
**
** ** ** ** **
**
**
**
7 13 19 25 31 37 43 49 55 61 67 73 79 85 910
Le
as
t S
qu
ar
es
 M
ea
n 
Ch
an
ge
Fr
om
 B
as
el
in
e 
(9
5%
 C
I)
No. at risk: 107 100 85 78 76 68 69 72 58 44 31 16 10 11 10 10
–40
–30
–20
–10
0
10
20
30
B
et
te
r
Time (weeks)
W
o
rs
e
**
** **
******
**
** ** ** ** ** ** **
7 13 19 25 31 37 43 49 55 61 67 73 79 85 910
Le
as
t S
qu
ar
es
 M
ea
n 
Ch
an
ge
Fr
om
 B
as
el
in
e 
(9
5%
 C
I)
No. at risk: 107 99 85 79 76 68 69 72 58 45 31 16 10 11 10 10
–40
–30
–20
–10
0
10
20
30
B
et
te
r
Time (weeks)
W
o
rs
e
**
** ********
**
**
** ** **
*
**
**
**
7 13 19 25 31 37 43 49 55 61 67 73 79 85 910
Le
as
t S
qu
ar
es
 M
ea
n 
Ch
an
ge
Fr
om
 B
as
el
in
e 
(9
5%
 C
I)
No. at risk: 107 100 85 79 76 68 69 72 58 44 31 16 10 11 10 10
–30
–20
–10
0
10
20
30
40
Time (weeks)
**
** ********
**
**
**
**
** ** ** **
B
et
te
r
W
o
rs
e
7 13 19 25 31 37 43 49 55 61 67 73 79 85 910
Le
as
t S
qu
ar
es
 M
ea
n 
Ch
an
ge
Fr
om
 B
as
el
in
e 
(9
5%
 C
I)
No. at risk: 107 98 84 78 75 67 68 71 57 45 31 16 10 11 10 10
–30
–20
–10
0
10
20
30
40
Time (weeks)
**
**
**
**
****
**
** ** **
**
** *
**
**
B
et
te
r
W
o
rs
e
7 13 19 25 31 37 43 49 55 61 67 73 79 85 910
Le
as
t S
qu
ar
es
 M
ea
n 
Ch
an
ge
Fr
om
 B
as
el
in
e 
(9
5%
 C
I)
No. at risk: 107 99 85 79 76 68 69 72 58 45 31 16 10 11 10 10
–30
–20
–10
0
10
20
30
40
Time (weeks)
**
**
****
****
**
** **
**
**
** **
**
**
B
et
te
r
W
o
rs
e
7 13 19 25 31 37 43 49 55 61 67 73 79 85 910
Le
as
t S
qu
ar
es
 M
ea
n 
Ch
an
ge
Fr
om
 B
as
el
in
e 
(9
5%
 C
I)
No. at risk: 107 100 85 79 76 68 69 72 58 44 31 16 10 11 10 10
–40
–30
–20
–10
0
10
20
30
B
et
te
r
Time (weeks)
W
o
rs
e
**
**
**
****
**** **
**
**
*
*
*
** **
7 13 19 25 31 37 43 49 55 61 67 73 79 85 910
A
C
E
G
B
D
F
H
Fig A4. Patient-reported outcomes:mean change from baseline per the EuropeanOrganisation for Research and Treatment of Cancer Core Quality of Life Questionnaire.
(A) Fatigue, (B), pain, (C) appetite loss, (D) constipation, (E) role functioning, (F) global health status/quality of life, (G) social functioning, (H) insomnia, (I) nausea/vomiting,
(J) dyspnea, (K) diarrhea, (L) cognitive functioning, and (M) physical functioning. (*) P , .05. (**) P , .01.
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Fig A5. Patient-reported outcomes: mean change from baseline per three-level
five-dimensional EuroQol instrument visual analog scale. (**) P , .01.
Table A1. ORR, Best Overall Response, and DCR per BICR (N = 119)
Response No. (%) 95% CI
ORR 58 (49) 39.5 to 58.1
Best overall response
Complete response 5 (4)
Partial response 53 (45)
Stable disease 39 (33)
Progressive disease 17 (14)
Not determined 4 (3)
Not reported 1 (1)
Disease control for $ 12 weeks 94 (79) 70.6 to 85.9
Abbreviations: BICR, blinded independent central review; DCR, disease control
rate; ORR, objective response rate.
Table A2. ORR and DCR in Biomarker-Defined Patient Populations per
Investigator Assessment (N = 119)
Biomarker
No. (%)
ORR
Disease Control
for $ 12 Weeks
Tumor PD-L1 expression
$ 1% (n = 26) 14 (54) 20 (77)
, 1% (n = 65) 34 (52) 51 (78)
Unknown (n = 28) 17 (61) 24 (86)
Mutation status
BRAF/KRAS wild type (n = 31) 17 (55) 24 (77)
BRAF mutant (n = 29) 16 (55) 23 (79)
KRAS mutant (n = 44) 25 (57) 37 (84)
Unknown (n = 15) 7 (47) 11 (73)
Clinical history of Lynch syndrome*
Yes (n = 35) 25 (71) 30 (86)
No (n = 31) 15 (48) 25 (81)
Unknown (n = 53) 25 (47) 40 (75)
Abbreviations: DCR, disease control rate; ORR, objective response rate; PD-L1,
programmed death-ligand 1.
*Lynch syndrome designation was based on the clinical records of the patients
at sites in countries where this reporting was permitted (excluded Italy).
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Table A6. Summary of Select Treatment-Related Adverse Events
Organ System
Patients With Event
No. (%)
Time to Onset (weeks)
Median (range)
Patients With
Resolution
No. (%)
Time to Resolution
Median (range)
Patients Who
Received Immune-
Modulating
Medication
No. (%)
Any Grade
Grade
3-4 Any Grade
Grade
3-4 Any Grade
Grade
3-4 Any Grade
Grade
3-4 Any Grade
Grade
3-4
Skin 34 (29) 5 (4) 5.2 (0.3-38) 2.1 (1-23) 24 (71) 5 (100) 9.0 (0.4-106) 2.6 (1-13) 19 (56) 4 (80)
Endocrine 30 (25) 6 (5) 9.1 (3-42) 13.1 (8-20) 12 (40) 3 (50) Not reached (2-93) Not reached (2-48) 11 (37) 4 (67)
GI 27 (23) 4 (3) 9.1 (0.3-41) 16.1 (4-38) 25 (96) 4 (100) 1.5 (0.1-28) 1.1 (1-3) 6 (22) 3 (75)
Hepatic 23 (19) 13 (11) 7.0 (1-42) 10.0 (3-42) 17 (74) 11 (85) 5.0 (0.3-66) 3.3 (1-57) 10 (43) 9 (69)
Pulmonary 6 (5) 1 (1) 10.5 (4-15) 6.0 (6-6) 5 (83) 1 (100) 4.5 (1-49) 1.0 (1-1) 2 (33) 0
Renal 6 (5) 2 (2) 12.6 (1-36) 15.6 (7-24) 5 (83) 1 (50) 6.3 (3-21) Not reached (4-21) 2 (33) 2 (100)
NOTE. Treatment-related adverse events were assessed during treatment and for up to 30 days after the last dose of study treatment according to the National Cancer
Institute Common Terminology Criteria for Adverse Events (version 4.0).
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